SCHEMBL5916689

SCHEMBL5916689

O=c1c2c(F)cccc2[se]n1-c1cccnc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 1/20 0.47
▸ HTT P42858 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ METAP2 P50579 3/20 0.42
▸ EP300 Q09472 1/20 0.39
▸ KAT2B Q92831 1/20 0.39
▸ ALOX12 P18054 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ QSOX1 O00391 1/20 0.39
▸ RGS12 O14924 1/20 0.39
▸ PMM2 O15305 1/20 0.39
▸ PLIN1 O60240 1/20 0.39
▸ GMNN O75496 1/20 0.39
▸ BBOX1 O75936 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5916710 0.84 APP (0.46) APPHTTMAPTHSD17B10METAP2
SCHEMBL5916757 0.83 HTT (0.43) APPHTTMAPTHSD17B10GAA
SCHEMBL5916664 0.83 HTT (0.43) APPHTTMAPTHSD17B10GAA
SCHEMBL5916835 0.82 METAP2 (0.57) APPHTTMAPTHSD17B10METAP2
SCHEMBL5916543 0.78 METAP2 (0.42) HTTMAPTHSD17B10GAAMAPK1
SCHEMBL5916907 0.77 METAP2 (0.68) HTTMAPTHSD17B10METAP2ALOX12
SCHEMBL5916700 0.75 METAP2 (0.55) HTTMAPTHSD17B10METAP2ALOX12
SCHEMBL5916570 0.74 METAP2 (0.53) HTTMAPTHSD17B10METAP2ALOX12
SCHEMBL5916666 0.73 APP (0.50) APPGAAMAPK1METAP2EP300
SCHEMBL5917044 0.69 METAP2 (0.45) HTTMAPTHSD17B10METAP2ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US claimed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP claimed
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US disclosed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage TNNI3, TNNT2, MYLK2 APP 4876/4885HTT 4854/4885MAPT 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback